January 9, 2013, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study,…Details
TapImmune Chairman Provides Corporate Update Including Progress on Clinical Trial Program and Scientific Collaborations.
November 5, 2012, Seattle, WA. TapImmune Inc. (OTCBB: TPIV) Chairman and CEO Glynn Wilson, Ph.D., is pleased to provide this corporate update to our shareholders and other interested parties: To our current and future shareholders, I am pleased to take this opportunity to update the progress we have made over the past few months. A…Details
Vaccinomics – The matching of individual immune response genetics to specific target peptides in vaccines. Designs for success. The field of immunology and vaccine design has reached a new paradigm of understanding as to how vaccines work, or don’t work, based on our understanding of immune response genetics. In principle the genetic variables, or ‘alleles’…Details
Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012
June 25, 2012, Seattle, WA, TapImmune Inc (OTCBB: TPIV) has announced it will present a poster at the Third Annual Cancer Vaccines and Active Immunotherapy Summit in Boston describing it’s Her-2/Neu vaccine development program. This will include scientific details describing and differentiating this vaccine program from others in clinical development. The prime and boost approach…Details
Seattle, WA, TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease, announces that Dr. Glynn Wilson, Chairman & CEO, will present at the NYC MedTech Program, a medical technology and life science forum founded by John Lieberman CPA, Managing Director of…Details
TapImmune Inc. (OTCBB: TPIV) has pleasure in announcing the appointment of James W. Fuller to the Board of Directors. James (Jim) Fuller has over 30 years of experience in the brokerage and related financial services industries. His financial career started at J. Barth & Company, a New York based investment banking and trading firm where…Details
TapImmune Inc. (OTCBB: TPIV) has announced that following recent IRB approval a Phase I Clinical Trial on a novel set of HER2/neu Class II antigens will start at Mayo Clinic, Rochester MN. Mayo Clinic received IND allowance from the FDA for this trial in 2011. TapImmune is sponsoring the Phase I study and has an…Details
April 30, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has pleasure in announcing the appointment of Mark Reddish to the Board of Directors. Mark is currently Vice President of Development at TapImmune and is responsible for developing the Company’s product pipeline. He was formerly Vice President of Research & Development and Principal Investigator, Biodefense at…Details
Former Special Advisor to the UK Treasury Department to join TapImmune’ s Advisory Team April 19, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has pleasure in announcing the appointment of George Cardona as a Strategic Advisor to the Board on corporate strategy and financial matters. Mr. Cardona has extensive experience in banking and government. He…Details
TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer.
Addition of Class I antigen provides new advance in development of HER2/neu vaccines. April 16, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. This antigen was discovered…Details